MA37849A1 - Dérivés de diazépinone à utiliser pour le traitement du syndrome de l'x fragile, de la maladie de parkinson ou de la maladie du reflux - Google Patents
Dérivés de diazépinone à utiliser pour le traitement du syndrome de l'x fragile, de la maladie de parkinson ou de la maladie du refluxInfo
- Publication number
- MA37849A1 MA37849A1 MA37849A MA37849A MA37849A1 MA 37849 A1 MA37849 A1 MA 37849A1 MA 37849 A MA37849 A MA 37849A MA 37849 A MA37849 A MA 37849A MA 37849 A1 MA37849 A1 MA 37849A1
- Authority
- MA
- Morocco
- Prior art keywords
- disease
- parkinson
- syndrome
- treating fragile
- diazepinone derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Abstract
L'invention concerne un composé de formule (i) ou un sel de celui-ci, pour lequel les substituants sont tels que définis dans la description ; sa préparation, son utilisation en tant que médicament et des médicaments le comprenant.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1215033.0A GB201215033D0 (en) | 2012-08-23 | 2012-08-23 | Diazepinone derivatives |
PCT/IB2013/056782 WO2014030128A1 (fr) | 2012-08-23 | 2013-08-21 | Dérivés de diazépinone à utiliser pour le traitement du syndrome de l'x fragile, de la maladie de parkinson ou de la maladie du reflux |
Publications (1)
Publication Number | Publication Date |
---|---|
MA37849A1 true MA37849A1 (fr) | 2017-09-29 |
Family
ID=47045285
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA37849A MA37849A1 (fr) | 2012-08-23 | 2013-08-21 | Dérivés de diazépinone à utiliser pour le traitement du syndrome de l'x fragile, de la maladie de parkinson ou de la maladie du reflux |
Country Status (44)
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201215033D0 (en) | 2012-08-23 | 2012-10-10 | Novartis Ag | Diazepinone derivatives |
US11878001B2 (en) | 2017-07-31 | 2024-01-23 | Novartis Ag | Use of mavoglurant in the reduction of ***e use or in preventing relapse into ***e use |
EA202191812A1 (ru) | 2019-01-29 | 2021-10-25 | Новартис Аг | ПРИМЕНЕНИЕ АНТАГОНИСТА mGluR5 ДЛЯ ЛЕЧЕНИЯ ТОЛЕРАНТНОСТИ К ОПИОИДНЫМ АНАЛЬГЕТИКАМ |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3853851A (en) * | 1972-01-26 | 1974-12-10 | Ciba Geigy Corp | Diazepinoisoquinolines |
GB0128996D0 (en) | 2001-12-04 | 2002-01-23 | Novartis Ag | Organic compounds |
CN100457731C (zh) * | 2003-03-26 | 2009-02-04 | 麦克公司 | 代谢型谷氨酸受体的苯甲酰胺调节剂 |
GB0413605D0 (en) * | 2004-06-17 | 2004-07-21 | Addex Pharmaceuticals Sa | Novel compounds |
TW200811157A (en) * | 2006-05-05 | 2008-03-01 | Astrazeneca Ab | mGluR5 modulators I |
CU20090172A7 (es) | 2009-10-09 | 2011-10-05 | Ct De Investigación Y Desarrollo De Medicamentos | Sistemas tricíclicos y tetracíclicos con actividad sobre el sistema nervioso central y vascular |
WO2011075699A2 (fr) * | 2009-12-18 | 2011-06-23 | Sunovion Pharmaceuticals Inc. | Composés pour le traitement des troubles médiés par le récepteur métabotropique 5 du glutamate, et leurs méthodes d'utilisation |
EP2708540B1 (fr) | 2011-05-10 | 2018-07-25 | Kyowa Hakko Kirin Co., Ltd. | Composé pyrimido-diazépinone |
GB201215033D0 (en) * | 2012-08-23 | 2012-10-10 | Novartis Ag | Diazepinone derivatives |
-
2012
- 2012-08-23 GB GBGB1215033.0A patent/GB201215033D0/en not_active Ceased
-
2013
- 2013-08-21 MY MYPI2014003502A patent/MY170103A/en unknown
- 2013-08-21 EA EA201590415A patent/EA029493B1/ru not_active IP Right Cessation
- 2013-08-21 UA UAA201413654A patent/UA114326C2/uk unknown
- 2013-08-21 AP AP2014008140A patent/AP2014008140A0/xx unknown
- 2013-08-21 PL PL13783671T patent/PL2888259T3/pl unknown
- 2013-08-21 MX MX2015002367A patent/MX365253B/es active IP Right Grant
- 2013-08-21 DK DK13783671.4T patent/DK2888259T3/en active
- 2013-08-21 RS RS20180581A patent/RS57231B1/sr unknown
- 2013-08-21 PT PT137836714T patent/PT2888259T/pt unknown
- 2013-08-21 AU AU2013307239A patent/AU2013307239B2/en not_active Ceased
- 2013-08-21 CN CN201380042195.XA patent/CN104520298B/zh active Active
- 2013-08-21 LT LTEP13783671.4T patent/LT2888259T/lt unknown
- 2013-08-21 NO NO13783671A patent/NO2888259T3/no unknown
- 2013-08-21 BR BR112015003281A patent/BR112015003281A8/pt active Search and Examination
- 2013-08-21 JP JP2015527996A patent/JP6169699B2/ja not_active Expired - Fee Related
- 2013-08-21 PE PE2015000245A patent/PE20150401A1/es active IP Right Grant
- 2013-08-21 WO PCT/IB2013/056782 patent/WO2014030128A1/fr active Application Filing
- 2013-08-21 KR KR1020157003903A patent/KR102104149B1/ko active IP Right Grant
- 2013-08-21 HU HUE13783671A patent/HUE037971T2/hu unknown
- 2013-08-21 TR TR2018/07174T patent/TR201807174T4/tr unknown
- 2013-08-21 NZ NZ703628A patent/NZ703628A/en not_active IP Right Cessation
- 2013-08-21 MA MA37849A patent/MA37849A1/fr unknown
- 2013-08-21 SG SG11201500068QA patent/SG11201500068QA/en unknown
- 2013-08-21 SI SI201331027T patent/SI2888259T1/en unknown
- 2013-08-21 EP EP13783671.4A patent/EP2888259B1/fr active Active
- 2013-08-21 CA CA2878564A patent/CA2878564C/fr active Active
- 2013-08-21 SG SG10201701333WA patent/SG10201701333WA/en unknown
- 2013-08-21 ES ES13783671.4T patent/ES2672737T3/es active Active
- 2013-08-22 US US13/973,454 patent/US8853203B2/en active Active
- 2013-08-22 TW TW102130096A patent/TWI616444B/zh not_active IP Right Cessation
- 2013-08-22 JO JOP/2013/0250A patent/JOP20130250B1/ar active
- 2013-08-22 UY UY0001034986A patent/UY34986A/es unknown
- 2013-08-23 AR ARP130102989A patent/AR092212A1/es not_active Application Discontinuation
-
2014
- 2014-08-19 US US14/462,813 patent/US9284331B2/en active Active
- 2014-12-18 ZA ZA2014/09345A patent/ZA201409345B/en unknown
- 2014-12-19 TN TN2014000528A patent/TN2014000528A1/fr unknown
-
2015
- 2015-02-02 IL IL237062A patent/IL237062A/en active IP Right Grant
- 2015-02-20 PH PH12015500373A patent/PH12015500373B1/en unknown
- 2015-02-20 CL CL2015000416A patent/CL2015000416A1/es unknown
- 2015-02-23 CU CUP2015000016A patent/CU20150016A7/es unknown
- 2015-02-23 CR CR20150092A patent/CR20150092A/es unknown
- 2015-02-23 GT GT201500039A patent/GT201500039A/es unknown
- 2015-07-02 HK HK15106284.5A patent/HK1206008A1/xx not_active IP Right Cessation
-
2016
- 2016-02-12 US US15/042,924 patent/US9650377B2/en active Active
-
2017
- 2017-04-28 US US15/581,642 patent/US20170305903A1/en not_active Abandoned
- 2017-06-28 JP JP2017125822A patent/JP2017226661A/ja not_active Withdrawn
-
2018
- 2018-05-29 HR HRP20180850TT patent/HRP20180850T1/hr unknown
- 2018-06-07 CY CY181100599T patent/CY1120728T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA39783A (fr) | Dérivés de quinoxaline utiles en tant que modulateurs de la fgfr kinase | |
MA47217B1 (fr) | Composés de n-((hét)arylméthyl)hétéroaryle-carboxamides en tant qu'inhibiteurs de la kallicréine plasmatique | |
MA38661A1 (fr) | Composés hétéro-aromatiques et leur utilisation en tant que ligands d1 de la dopamine | |
MA42230B1 (fr) | Dérivés bicycliques, leur procédé de préparation, et compositions pharmaceutiques les contenant | |
MA40123A1 (fr) | Pyrimidines utilisées en tant qu'inhibiteurs du facteur xia | |
MA40523B1 (fr) | 2-(morpholin-4-yl)-1,7-naphthyridines | |
MA42341A1 (fr) | Inhibiteur de protéine kinase, son procédé de préparation et son utilisation médicale | |
MA40225B1 (fr) | Composés dihydroisoquinolinone substitués | |
UA113051C2 (xx) | Гетероциклічні похідні та їх застосування у лікуванні неврологічних розладів | |
MA41238B1 (fr) | Dérivés 5-[(pipérazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione en tant qu'inhibiteurs d'adamts pour le traitement de l'ostéoarthrit | |
MA33450B1 (fr) | Dérivés d'oxazine et leur utilisation en tant qu'inhibiteurs de bace pour le traitement de troubles neurologiques | |
MA47356B1 (fr) | Dérivés d'isochromène utiles en tant qu'inhibiteurs des phosphoinositide 3-kinases | |
MA34361B1 (fr) | Dérivés de tétrahydro-pyrido-pyrimidine | |
MA40955B1 (fr) | 2-amino-6-(difluorométhyl)-5,5-difluoro-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1 | |
MA40875A (fr) | 2,4-diamino-quinoléine substituée servant de nouveaux agents anticancéreux | |
MA39170A1 (fr) | Composes inhibiteurs de sérine/thréonine kinase pour leurs utilisations dans le traitement du cancer | |
MA43913B1 (fr) | Modulateurs allostériques positifs du récepteur m1 muscarinique | |
MA38358A1 (fr) | Formulations de composés organiques | |
MA38410B1 (fr) | Composés d'azétidinyloxyphénylpyrrolidine | |
MA38307A1 (fr) | 4-hydroxy-2-méthyl-5-(propan-2-ylidène)cyclohex-3-ènecarbaldéhyde pour la prévention et le traitement d'une maladie cognitive, neurodégénérative ou neuronale | |
MA37849A1 (fr) | Dérivés de diazépinone à utiliser pour le traitement du syndrome de l'x fragile, de la maladie de parkinson ou de la maladie du reflux | |
MA38250A1 (fr) | Nouveau dérivés d'hydantoïne pour leurs utilisations dans le traitement de maladies, comme l'osteoporose et la thrombocytopenie | |
MA39229A1 (fr) | Pyrrolidines, térahydrofuranes et cyclopentanes substitués utiles en tant qu'antagonistes des récepteurs des orexines | |
MA41975B1 (fr) | Derives d'aminohydrothiazine fusionnee contenant du tetrahydrofurane utiles dans le traitement de la maladie d'alzheimer | |
MA37999B1 (fr) | Dérivés de macrolide, leur préparation et leur utilisation thérapeutique |